"Our name is changing. During this transition period you may see either University of Michigan Health-West OR Metro Health- University of Michigan Health on patient communications and billing statements."

During the past decade, Metro Health Cancer Care conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Metro Health Cancer Care" #1 sponsor was "Hoosier Cancer Research Network" with 2 trials, followed by "Ajjai Alva, MD" with 1 trials sponsored, "Alaunos Therapeutics" with 1 trials sponsored, "Infinity Pharmaceuticals, Inc." with 1 trials sponsored and "Matthew Galsky" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Metro Health Cancer Care" #1 collaborator was "Hoosier Cancer Research Network" with 3 trials as a collaborator, "Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma" with 1 trials as a collaborator, "Bionomics Limited" with 1 trials as a collaborator, "Cephalon" with 1 trials as a collaborator and "Clovis Oncology, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Metro Health Cancer Care" are "Bladder Carcinoma" (1 trials), "Bone Metastases" (1 trials), "Breast Cancer" (1 trials), "Extensive-Stage Small Cell Lung Cancer" (1 trials) and "Multiple Myeloma" (1 trials). Many other conditions were trialed in "Metro Health Cancer Care" in a lesser frequency.

Most popular intervention types in "Metro Health Cancer Care" are "Drug" (7 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Everolimus" (2 trials), "BNC105P" (1 trials), "Bendamustine" (1 trials), "Bicalutamide" (1 trials) and "Bortezomib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Metro Health Cancer Care" are 6 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Metro Health Cancer Care". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Metro Health Cancer Care, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Metro Health Cancer Care, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".